The first 10 publications according to Impact factor (I.F.) for the last four years:
-
Maio M., Ascierto P.A., Manzyuk L., Motola-Kuba D., Penel N., Cassier P.A. et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Annals of Oncology. 2022;33(9):929-938.
PUBMED
DOI
-
Grande E., Arranz J.A., De Santis M., Bamias A., Kikuchi E., del Muro X.G. et al. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study. The Lancet Oncology. 2024;25(1):29-45.
PUBMED
DOI
-
Bamias A., Davis I.D., Galsky M.D., Arranz J.A., Kikuchi E., Grande E. et al. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study. The Lancet Oncology. 2024;25(1):46-61.
PUBMED
DOI
-
Van Laethem J.-L., Borbath I., Prenen H., Geboes K.P., Lambert A., Mitry E. et al. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study. The Lancet Oncology. 2024;.
PUBMED
DOI
-
Overbeek K.A., Goggins M.G., Dbouk M., Levink I.J.M., Koopmann B.D.M., Chuidian M. et al. Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. Gastroenterology. 2022;162(3):772-785.e4.
PUBMED
DOI
-
Koutros S., Kiemeney L.A., Pal Choudhury P., Milne R.L., Lopez de Maturana E., Ye Y. et al. Genome-wide Association Study of Bladder Cancer Reveals New Biological and Translational Insights. European Urology. 2023;84(1):127-137.
PUBMED
DOI
-
Alonso-Nocelo M., Ruiz-Canas L., Sancho P., Gorgulu K., Alcala S., Pedrero C. et al. Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma. Gut. 2022;.
PUBMED
DOI
-
Kartal E., Schmidt T.S.B., Molina-Montes E., Rodriguez-Perales S., Wirbel J., Maistrenko O.M. et al. A faecal microbiota signature with high specificity for pancreatic cancer. Gut. 2022;.
PUBMED
DOI
-
Marabelle A., O'Malley D.M., Hendifar A.E., Ascierto P.A., Motola-Kuba D., Penel N. et al. Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial. Nature Cancer. 2025;.
PUBMED
DOI
-
Lopez-Gil J.C., Garcia-Silva S., Ruiz-Canas L., Navarro D., Palencia-Campos A., Giraldez-Trujillo A. et al. The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells. Gut. 2024;.
PUBMED
DOI